{
    "2019-04-30": [
        [
            {
                "time": "",
                "original_text": "证券监管政策持续加码 上海领灿携标杆案例逆势增长30%",
                "features": {
                    "keywords": [
                        "证券监管",
                        "政策",
                        "上海领灿",
                        "标杆案例",
                        "逆势增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融",
                        "证券"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "细数2018年研发投入超10亿的中国药企",
                "features": {
                    "keywords": [
                        "2018年",
                        "研发投入",
                        "中国药企"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "抢跑4+7第二批目录 上药盐酸二甲双胍过一致性评价",
                "features": {
                    "keywords": [
                        "4+7",
                        "第二批目录",
                        "上药",
                        "盐酸二甲双胍",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【审评】降糖“神药”又有2家企业过评，15亿大品种施维雅受冲击",
                "features": {
                    "keywords": [
                        "审评",
                        "降糖药",
                        "企业过评",
                        "施维雅",
                        "冲击"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "瑞信：微降上海医药(02607)目标价至18.14港元 维持“中性”评级",
                "features": {
                    "keywords": [
                        "瑞信",
                        "上海医药",
                        "目标价",
                        "中性评级"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【银河国际】上海医药[2607.HK] 一季度业绩良好；评级维持买入",
                "features": {
                    "keywords": [
                        "银河国际",
                        "上海医药",
                        "一季度业绩",
                        "买入评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "公告点题｜4月29日这些公告有看头",
                "features": {
                    "keywords": [
                        "公告",
                        "4月29日"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}